Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Allergan Hopes To Add Bipolar Depression To Vraylar's Label

Executive Summary

With Phase III success in bipolar depression, Allergan plans an sNDA in 2018 to add that indication to the atypical antipsychotic's label, which includes schizophrenia and bipolar mixed or manic episodes.


Related Content

Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow
Allergan Readies Cost Cuts As Restasis Generics Approach
Allergan Urgently Seeks FDA Guidance To Unblock Vraylar sNDA Review
Uphill Climb For Gedeon Richter's Cariprazine After Delayed EU OK
Allergan, Gedeon Richter Unbowed By Cariprazine MDD Phase III Trial Failure
Allergan/Richter’s Antipsychotic Vraylar Offers New Mechanism Of Action


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts